Market overview:
The large number of births occurring globally and growth in GDP & disposable income are expected to further boost the market growth. Over 170 different cord blood banking service providers are offering services in different regions of the world. Market growth has been fueled due to Increase in prevalence of fatal chronic diseases, growing patient population, and regulatory complications are the major restraints.
The key players operating in the global stem cell banking market include Cord Blood Registry, ViaCord, Cryo-Cell, China Cord Blood Corporation, Cryo-Save, New York Cord Blood Program, CordVida, Americord, CryoHoldco, and Vita34. Other prominent players in the value chain include Caladrius Biosciences, Cryoviva, Smart Cells International Ltd., Stemade Biotech, Cellular Dynamics International.
Segmentation:
cells, Adult stem cells, and Embryonic stem cells
Embryonic stem cells come from human embryos that are three to five days old. This involves fertilizing an embryo in a laboratory instead of inside the female body. Embryonic stem cells are known as pluripotent stem cells. Umbilical cord blood collected at birth is a rich source of stem cells that can be used in research and in the clinic to treat diseases of the blood and immune system
Bank Type: Public, Private
By Service Type: Collection and Transportation, Processing, Analysis, Storage
By Geography: Americas, APAC,EMEA
North America leading market share to the global stem cell banking due to the advanced medical infrastructure and increasing awareness about the stem cell preservations. Followed by North America, Europe has also registered the significant growth to the global stem cell banking market. The Asia Pacific region has expected to show a robust growth over a forecast period due to rapidly developing medical facilities and services in the countries such as Japan, China and India. The rising power of per capita expenditure on healthcare facilities in the APAC also expected to fuel the growth of the global stem cell banking market in the region. Latin America and MEA are at a beginning stage and expected to a significant growth over the forecast period.
Report Description: The report covers in-depth analysis on Global Stem Cell Banking. The report assesses global stem cell banking market by cell type (Umbilical cord stem cells, Adult stem cells, and Embryonic stem cells). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement patent, and regulatory designations.
The report includes in-depth company profiles of key players in Global Stem Cell Banking. The company profile includes key information on overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Scope:
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market Triangulation
Forecasting
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.
